Next Article in Journal
Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review
Previous Article in Journal
Optimizing ctDNA: An Updated Review of a Promising Clinical Tool for the Management of Uveal Melanoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 17
10.3390/cancers16173054
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview

by
Tadeusz Robak
1,2,*,
Marcin Braun
3,
Agnieszka Janus
2,
Anna Guminska
4 and
Ewa Robak
5
1
Department of Hematology, Medical University of Lodz, 91-738 Lodz, Poland
2
Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland
3
Department of Pathology, Medical University of Lodz, 92-213 Lodz, Poland
4
Department of Nuclear Medicine, Copernicus Memorial Hospital, 93-513 Lodz, Poland
5
Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(17), 3054; https://doi.org/10.3390/cancers16173054
Submission received: 8 August 2024 / Revised: 29 August 2024 / Accepted: 30 August 2024 / Published: 1 September 2024
(This article belongs to the Special Issue Hairy Cell Leukemia and Related Disorders—Current Progress in Biology and Treatment)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Diagnosis of hairy cell leukemia is based on the presence of hairy cells in bone marrow and peripheral blood as well as the characteristic immunophenotype. Moreover, in classic HCL, most patients present with a BRAF V600E mutation. The typical symptoms of classic hairy cell leukemia include pancytopenia, massive splenomegaly and increased risk of infection. However, rarer manifestations of HCL are occasionally reported, including cutaneous symptoms, bone infiltration, arthritis and central nervous system symptoms, as well as gastrointestinal tracts, heart, lungs, ocular involvement and other symptoms.

Abstract

Background: Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoid malignancy. The majority of patients are asymptomatic and HCL is usually diagnosed incidentally during a routine blood cell count. In symptomatic patients, typical symptoms are related to pancytopenia and splenomegaly. In this review, we present rare clinical symptoms in patients with HCL. Methods: A literature search was conducted of PubMed, Web of Science and Google Scholar for articles concerning hairy cell leukemia, leukemia cutis, bone lesions, neurological manifestations, pulmonary symptoms, ocular manifestations, cardiac manifestation and rare symptoms. Publications from January 1980 to August 2024 were scrutinized. Additional relevant publications were obtained by reviewing the references from the chosen articles. Results: Extramedullary and extranodal manifestations of classic HCL are rare. However, leukemic involvement in the skin, bone, central nervous system, gastrointestinal tract, heart, kidney, liver, lung, ocular system and other organs have been reported.

1. Introduction

Classic hairy cell leukemia (HCL) is a rare, indolent B-cell leukemia that makes up about 2% of all cases, with an annual incidence of about 0.3 cases per 100,000 [1,2,3,4,5]. HCL occurs more predominantly in middle age, with a median age of diagnosis of 56 years (range: 40–70 years) [1,2]. The disease is extremely rare in younger patients; however, a few cases of HCL have been reported in children [6]. Diagnosis is based on peripheral blood (PB) and bone marrow (BM) morphology, flow cytometry, immunophenotyping, immunohistochemistry and molecular studies [1,2,7,8]. The majority of patients with HCL are asymptomatic at diagnosis and the disease is usually found incidentally during routine blood cell counts. The typical clinical presentation of classic HCL involves pancytopenia, monocytopenia, splenomegaly, constitutional symptoms and increased risk of infection [1,2]. In most patients, lymph nodes are not enlarged; however, an atypical presentation, such as the absence of splenomegaly and the presence of lymphadenopathy and leukocytosis, may also be observed in some patients. Typical hairy cells are medium in size with moderately abundant pale blue cytoplasm with a characteristic serrated cytoplasmic border, reniform nuclei, open chromatin and absent nucleoli [1,2,9,10,11,12,13]. The characteristic immunophenotype of classic HCL cells includes the co-expression of CD19, CD20, CD11c, CD25, CD103, CD200, FMC7 and CD123. The unique criterion for the diagnosis of HCL is the co-expression of CD103, CD25 and CD11c. Also, HCL can be distinguished from other B-cell lymphomas, including HCLv, based on annexin A1 expression; indeed, it has been reported that Annexin A1 is a 100% specific immunohistochemical marker for classic HCL [7]. The BRAF V600E mutation is present in almost all HCL patients and plays a key role in the pathogenesis of this disease [8]. Extramedullary and extranodal manifestations of classic HCL are rare events [9,10]. However, leukemic involvement in the skin, bone, central nervous system, gastrointestinal tract, heart, kidney, liver, lung, ocular system and other organs have been reported [10,11,12,13] (Table 1).
HCL variant (HCLv) is a clinical–pathologic entity with intermediate features between classic HCL and B-cell prolymphocytic leukemia [92,93,94,95,96,97,98]. In the fifth edition of the WHO classification (WHO-HAEM5), classic HCL is classified as splenic lymphoma/leukemia, together with splenic marginal zone lymphoma (SMZL) with circulating villous cells in peripheral blood (PB), splenic lymphoma with a prominent nucleolus (SLPN) and splenic diffuse red pulp lymphoma (SDRPL) [94]. In this classification, HCLv is included as SLPN together with CD5-negative B-prolymphocytic leukemia (B-PLL). However, HCLv still exists in the clinical International Consensual Classification (ICC) [95,96]. Cladribine and pentostatin have been the drugs of choice for more than 30 years for newly diagnosed HCL [4,99,100,101]. In relapsed patients, re-treatment with purine analogs, alone or in combination with rituximab, is still an acceptable option. However, re-treatment with single-agent purine analogs often results in shorter responses, with some patients becoming refractory to the drugs. For these patients, other treatment options can be considered, including interferon-α (IFN-α), rituximab, bendamustine, fludarabine and BRAF inhibitors, used alone or in combination [4,98].
This review presents some of the rare clinical symptoms reported in patients with classic HCL. A literature search was conducted of PubMed, Web of Science and Google Scholar for articles concerning hairy cell leukemia, leukemia cutis, bone lesions, neurological manifestations, pulmonary symptoms, ocular manifestations, cardiac manifestation and rare symptoms. Publications from January 1980 to August 2024 were scrutinized. Additional relevant publications were obtained by reviewing the references from the chosen articles.

2. Skin Symptoms

Cutaneous manifestations of HCL have been reported in about 10–12% of patients [14]. Skin symptoms may be specific to HCL or mostly non-specific, due to autoimmune reactions, infections and secondary neoplastic or drug-induced reasons. Specific cutaneous manifestations, known as leukemia cutis, are very rare and are defined as the direct infiltration of the epidermis, the dermis and the subcutaneous tissue by leukemic cells [14,15,16,17]. They can be manifested as disseminated erythematous maculopapules or nodules, ranging from violaceous to red-brown in color, or flesh-colored nodules, with central ulceration or infiltrative eruptions [14,15,16,17]. Skin changes are localized in one region or are disseminated in several parts of the skin, and are characterized microscopically as a perivascular mononuclear leukemic cell infiltration. In patients with HCL, the diagnosis of leukemia cutis is performed based on the histopathology of skin biopsy and the immunophenotyping of neoplastic cells [17,18]. Skin biopsy and immunophenotyping must be performed in all patients with suspicion of leukemia cutis. Leukemia cutis should be differentiated from other cancers, vasculitis, infections and inflammation [19,20].
In most presented cases, specific treatment of HCL resulted in the disappearance of cutaneous infiltrates. Vasculitis is one of the more common non-specific skin changes in HCL patients [21,22,23], and vasculitis syndromes such as cutaneous leukocytoclastic vasculitis (CLCV), polyarteritis nodosa (PAN), pyoderma gangrenosum and paraneoplastic vasculitis have been noted in HCL and other lymphoid malignancies. Vasculitis can present as the initial manifestation of HCL or can be diagnosed in the course of disease [21,22,23,24]. Moreover, vasculitis may be a reaction to infection or a paraneoplastic syndrome related to HCL itself [25]. In one report of 42 HCL patients, CLCV was identified in 21 and PAN in 17 [26]. Neutrophilic dermatoses like Sweet’s syndrome, pyoderma gangrenosum and neutrophilic eccrine hidradenitis are rarely observed in HCL.
Sweet’s syndrome (acute febrile neutrophilic dermatosis), characterized by erythematous painful lesions that are sometimes in the form of plaques, has been reported as a presenting symptom at diagnosis or at relapse of HCL [27,28]. Pyoderma gangrenosum is a neutrophilic, reactive, non-infectious and inflammatory dermatosis involving the skin and mucosal tissue. It has been reported in a few cases with HCL. Pyoderma gangrenosum was successfully treated with cladribine without other immunosuppressive drugs such as cyclosporine or corticosteroids [102,103,104]. Elsewhere, Elkon et al. describe four patients with HCL and systemic vasculitis similar to polyarteritis nodosa that developed within two years of the onset of HCL [105], while Zervas et al. present a case of leukemia-associated polyarthritis [106].
Due to the increased risk of infections, the most common skin involvement in patients with HCL is due to bacterial or viral infections. However, verrucae, dermatophyte, candidal infections and pyogenic infections (i.e., abscesses, cellulitis, folliculitis and pyoderma) were also observed in some patients. Opportunistic skin infections, including atypical mycobacterial skin infections, fungal infections and Ecthyma gangrenosum have also been reported in HCL patients [14]. In most patients, prognosis is not affected by skin symptoms [14,15].

3. Bone Lesions

The most common orthopedic complications in HCL are due to osteolytic and osteoblastic lesions, severe osteoporosis, aseptic necrosis of the femoral head and multifocal lytic changes [29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]. Pathological femoral fractures and asymptomatic or painful diffuse osteosclerosis with extensive thickening of bone were also reported in some patients [35,36,37].
Skeletal infiltrations are observed in approximately 3% of HCL patients [38,39,40,41], and some patients present with skeletal infiltration at diagnosis [32,42]. However, in most patients, bone involvement is recognized between a few weeks and several years after diagnosis of HCL [38]. The median time from diagnosis of HCL to the manifestation of skeletal symptoms is 20 months (range: 0–93), although some patients have developed skeletal symptoms in complete hematological remission, and skeletal involvement has been found to develop 22 years after HCL diagnosis [31]. Some HCL patients with lytic bony lesions did not demonstrate splenomegaly [43,44].
Diagnosis and treatment evaluation of bone lesions is based on computed tomography (CT) and positron emission tomography (PET) (Figure 1.) [38]. Before the age of 18F-FDG PET/CT imaging, skeletal lesions were most commonly diagnosed by CT and magnetic resonance imaging (MRI), which were also used to evaluate the response to treatment. MRI is indicated in patients who have no roentgenographic or bone scan alterations, or they are non-specific [39,107]. More recently, 18F-FDG PET/CT imaging was recommended for diagnosis, staging and treatment assessment (Figure 1) [31,108]. PET is more specific and sensitive than other imaging methods, including CT and MRI, and is more helpful in differentiating HCL lesions from malignant bone tumors. Prognosis is usually not affected by bone leukemic infiltration [30,31]. To sum up, bone lesions in HCL can be early or appear over the years, and even in patients in remission.

4. Pulmonary Symptoms

Pulmonary involvement by HCL cells is a very rare condition (Figure 2), with only a few cases with leukemic lung infiltration being apparent in the literature [45,46,47,48,49,50,51,109]. A lung biopsy for histological examination is indicated in patients with pulmonary symptoms if antibiotics and antifungal treatment are not effective. However, a pulmonary biopsy is connected with the risk of bleeding and traumatic lung. Treatment with cladribine and/or rituximab induced a regression of leukemic pulmonary involvement in most patients [45,46,47,48,49,50]. However, the most common cause of pulmonary symptoms in HCL are infections [45]. Disseminated atypical mycobacterial infections were reported in several patients with HCL [51,109,110,111]. Clinically, pulmonary infiltrations were usually observed on chest X-rays in addition to fever and chills. Invasive diagnostic studies, including thoracotomy, can be required for the confirmation of the diagnosis of atypical mycobacterial infection with Mycobacterium kansasii, Mycobacterium avium-intracellulare and Mycobacterium chelone. Mediastinal lymphadenopathy and secondary pulmonary amyloidosis was also observed in some patients with HCL [10,51].
The concomitant occurrence of lung cancer and HCL were occasionally reported. In some patients, a BRAF-V600E-mutated lung adenocarcinoma coexisted with BRAF-mutated HCL [112,113]. These patients can be treated with BRAF-targeted therapy, including vemurafenib and dabrafenib.

5. Neurological Manifestations

Neurological complications were reported in approximately 5% of HCL patients [52], with the most common cause being infection. However, the direct invasion of leukemic cells to the central nervous system (CNS) is rare in HCL [52,53,54,55,56,57,58,59,60,61,62,63]. In HCL patients, CNS involvement is typically indicated by confusion, aphasia, headache, meningeal syndrome, motor ataxia, dizziness, weakness, confusion, slurred speech, frequent falls, facial droop, fatigue, blurry vision and acute delusional symptoms [53,54,55,56,57,58,59,60,61,62]. Studies have also reported HCL localization in brain parenchyma and/or meninges [53,57,58,62,63,64,65,66,67,68]. In most HCL patients, CNS involvement is unrelated to large cell lymphoma disease transformation unlike CLL [59,63,64,65]. Systemic therapy with purine analogs and CD20 antibodies or, more recently, with BRAF inhibitors, are usually effective in controlling HCL demonstrating CNS involvement [53,60,63,66].

6. Ocular Symptoms

Ocular involvement of HCL is extremely rare and only 12 cases have been reported so far [69,70,71,72,73,74]. Of the reported cases, most involved the globe, with only two affecting the orbital mass [74,75]. In three-fourths of the patients, ocular or orbital manifestations were identified at the diagnosis of HCL.
Panuveitis and retinal vasculitis coincident with HCL related to leukemic infiltration or bleeding have been noted in case reports [71,73,76], as has leukemic severe left-sided panuveitis with conjunctival and ciliary involvement in an HCL patient [76]. Local and systemic antibiotic therapy was ineffective, but rapid improvement was observed following treatment with cladribine.
Spontaneous subperiosteal orbital hematoma was also reported in an HCL patient with a history of orbital floor reconstruction due to orbital fracture [77]. The patient received cladribine monotherapy. Four months later, the clinical symptoms (proptosis and diplopia) had resolved and a near-complete resolution of the subperiosteal collection was seen in neuroimaging.
Retinopathy and visual disturbance due to intraretinal hemorrhage were reported as the initial symptom of HCL in a few patients [78,79]. In two cases, leukemic infiltration of the cornea was presented [80]. Also, orbital infections can develop, as HCL itself and antileukemic treatments are highly immunosuppressive. Therapy with cladribine induced an improvement of ocular complications in most patients [71,81].

7. Hearing Loss

Sudden hearing loss in patients with leukemia can be related to leukemic infiltration, hemorrhage and infection. El Enazi et al. reported a patient with acute sensorineural hearing loss as an initial manifestation of HCL [114]. The morphology, immunohistochemistry and flow cytometry of the BM confirmed the diagnosis of HCL. This is the only case of sudden hearing loss in HCL noted to date, although a few cases with chronic myeloid leukemia and CLL have been reported [115,116,117,118,119]. Most had unilateral hearing loss, as in the HCL patient.

8. Liver and Gastrointestinal Tract Symptoms

Hepatomegaly can be seen in up to 30% of HCL patients [7,120]. However, liver and gastrointestinal tract involvement has only rarely been reported in HCL patients. Dhanesar et al. describe a patient diagnosed with HCL involving the hepatic portal system during post-splenectomy evaluation approximately four years after initial HCL diagnosis [121]. A computed tomography scan of the abdomen showed a tumor in the hepatic portal and peri-portal regions with bile duct obstruction. Following biopsy of the liver mass, a diagnosis of HCL was established [122,123].
Sen et al. describe the first case report of an HCL patient manifesting clinically with duodenal involvement [124]. At HCL diagnosis, the patient had typical symptoms with pancytopenia and massive splenomegaly. A CT scan of the abdomen revealed thickening of the duodenum. Subsequent esophago-gastro-duodenoscopy (EGD) showed duodenal ulcerative inflammation. The duodenal biopsy demonstrated infiltration with HCL cells. Treatment with cladribine leaded to complete response, including the disappearance of duodenum involvement. In another report, Tariq et al. present the case of a patient with gastric cancer that had developed during treatment of hairy cell leukemia with moxetumomab pasudotox [125]. In upper gastrointestinal endoscopy, a gastric mass with irregular margins was observed and histopathological evaluation showed well-differentiated adenocarcinoma of the intestinal type.

9. Cardiac Manifestation

Progressive pericarditis and pleuritis in HCL patients at diagnosis was reported recently [126]. The symptoms completely resolved after treatment with purine analogs, with no recurrence observed during a five-year observation. In another report, Koczwara et al. present the case of a 42-year-old HCL patient who developed transient cardiac failure following treatment with cladribine [127]. Cladribine interferes with the cardiac adenylate cyclase pathway and can induce cardiac dysfunction in some patients [128].
At diagnosis, hairy cell leukemia can occassionally mimic infective endocarditis [129]. Ramasamy et al. reported a case of HCL with fever of unknown origin, splinter haemorrhages with vasculitis and moderate splenomegaly and cytopenia at diagnosis, suggesting infective endocarditis; however, the PB cultures and transthoracic echocardiogram were normal, and BM infiltration by CD19, CD25, CD11c, CD45 and CD103-positive lymphoid cells indicated a diagnosis of HCL [129]. Severe congestive heart failure was diagnosed in a patient with HCL treated with recombinant IFN-α2b [130]. Echocardiography showed severe global hypokinesis with second-degree mitral and aortic valve insufficiency and a reduced ejection fraction of 24%. The patient gradually improved after interferon was discontinued.

10. Rheumatological Manifestations

Rheumatological symptoms related either to hematological malignancy or disease-related immune dysregulation have rarely been reported in HCL patients [82,83,131]. The first patient with HCL and rheumatoid arthritis (RA) was reported in 1979 by Crofts et al.; in this case, rheumatoid arthritis had developed two years before HCL diagnosis [84]. Westbrook and Golde analyzed 37 HCL patients and identified 6 patients with joint symptoms, usually associated with nodular skin lesions; all patients responded promptly to antileukemic therapy [85]. Facchini et al. reported another patient who developed HCL eight years after RA diagnosis and suggested an association between autoimmune disease and HCL [86]. In another patient, immune RA developed five years after diagnosis of HCL [105]. More recently, Anil et al. reported bilateral knee swelling, erythema, tenderness and mild bilateral pedal edema before HCL diagnosis; the author reported spontaneous resolution of the rheumatism symptoms before anti-leukemic treatment, which indicated that they were immune-mediated [87]. In another case, a patient with HCL developed seropositive RA following treatment with IFN-α. In this case, the RA resolved over the next five months when interferon was administered for the HCL, with no exacerbation of the RA [88].
Zervas et al. presented a patient with HCL who developed seropositive RA [105]. In this patient, the RA resolved when interferon-a treatment was implemented, suggesting that RA with an autoimmune mechanism was directly related to HCL; however, HCL-associated arthritis with a non-immune mechanism has been documented in several patients [82,83,88,89,90,91]. Sattar et al. report the case of a patient with intermittent asymmetrical oligoarthritis who subsequently developed HCL [82]. Importantly, HCL cells were also detected in the synovial fluid, suggesting an association between arthritis and HCL. Raimbourg et al. observed another patient with osteoarticular symptoms among 27 patients with HCL [90]. This patient presented with polyarthritis involving the wrists, ankles and knees, which responded to non-steroidal anti-inflammatory drugs. Hairy cells were identified in the joint fluid, thus establishing a diagnosis of HCL-related arthritis. The presented cases suggest that arthritis can have an immune basis in some patients, but not in others. Prognosis is usually good as antileukemic and immunosuppressive treatment is effective.

11. Soft Tissue Involvement

Pilichowska et al. present the case of a patient with primary HCL of the breast, diagnosed incidentally during an elective reduction mammoplasty; the patient was asymptomatic without treatment one year following the HCL diagnosis [132]. In another patient, a pancreatic mass was observed under MRI nine years after HCL diagnosis and treatment with cladribine. An infiltrative lesion was reported along the pancreatic tail: it presented as a pancreatic mass partially encasing the pancreatic body, tail and splenic vessels, with an extension to the splenic hilum [133]. Fine-needle biopsy confirmed HCL infiltration.

12. Conclusions

In most patients, HCL is characterized by pancytopenia, splenomegaly and bone marrow infiltration. However, several other unusual symptoms of HCL are reported in the literature. These include extramedullary and extranodal manifestations of classic HCL in various organs including the skin, bones, central nervous system, gastrointestinal tract, heart, kidney, liver, lung and ocular system.

Author Contributions

Conceptualization, T.R. and E.R.; writing—original draft preparation, T.R. and E.R.; writing—review and editing, T.R., E.R., M.B., A.J., A.G. and E.R.; visualization, T.R., M.B., A.G. and E.R.; supervision, T.R.; funding acquisition, E.R. and T.R. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Medical University of Lodz, Poland (No. 503/1-093-01/503-11-004 and 503/1093-1/503-11-003).

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Lodz (No RNN/227/23/KE and No RNN/103/16/KE) for studies involving humans.

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The data presented in this study are available in this article.

Acknowledgments

We thank Edward Lowczowski from the Medical University of Lodz for editorial assistance and Aleksandra Samulska for technical assistance. We are grateful to the medical, nursing and laboratory staff of the participating departments for their contributions to this study.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Grever, M.R.; Abdel-Wahab, O.; Andritsos, L.A.; Banerji, V.; Barrientos, J.; Blachly, J.S.; Call, T.G.; Catovsky, D.; Dearden, C.; Demeter, J.; et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017, 129, 553–560. [Google Scholar] [CrossRef] [PubMed]
  2. Robak, T.; Matutes, E.; Catovsky, D.; Zinzani, P.L.; Buske, C.; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015, 26 (Suppl. S5), v100–v107. [Google Scholar] [CrossRef] [PubMed]
  3. Zakarija, A.; Peterson, L.C.; Tallman, M.S. Chapter 84-Hairy cell leukaemia. In Hematology: Basic Principles and Practice, 5th ed.; Hoffman, R., Benz, E.J., Shatil, S.J., Furie, B., Silberstein, L.E., McGlave, P., Heslop, H., Eds.; Churchill livingStone/Elsevier: Philadelphia, PA, USA, 2009; pp. 1349–1358. [Google Scholar]
  4. Puła, A.; Robak, T. Hairy cell leukemia: A brief update on current knowledge and treatment prospects. Curr. Opin. Oncol. 2021, 33, 412–419. [Google Scholar] [CrossRef]
  5. Gupta, R.; Yadav, S.; Mittal, N.; Rahman, K.; Sharma, A.; Gupta, A.; Nityan, S. Clinicopathological spectrum of hairy-cell leukemia: A single-center study with brief review of Indian literature. J. Cancer Res. Ther. 2020, 16, 120–126. [Google Scholar] [CrossRef] [PubMed]
  6. Bosma, M.; Bartels, M. Hairy cell leukemia in a child?! Blood 2018, 132, 1216. [Google Scholar] [CrossRef] [PubMed]
  7. Falini, B.; Tiacci, E.; Liso, A.; Basso, K.; Sabattini, E.; Pacini, R.; Foa, R.; Pulsoni, A.; Dalla Favera, R.; Pileri, S. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004, 363, 1869–1870. [Google Scholar] [CrossRef]
  8. Tiacci, E.; Trifonov, V.; Schiavoni, G.; Holmes, A.; Kern, W.; Martelli, M.P.; Pucciarini, A.; Bigerna, B.; Pacini, R.; Wells, V.A.; et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 2011, 364, 2305–2315. [Google Scholar] [CrossRef]
  9. Pattnaik, S.A.; Padhi, S.; Chhabra, G.; Panigrahi, M.K.; Das, P.K.; Bhola, R.K.; Mishra, S. Atypical presentation of hairy cell leukemia: A report and comprehensive review. Blood Res. 2020, 55, 123–127. [Google Scholar] [CrossRef] [PubMed]
  10. Polliack, A. Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and associated disorders. Rev. Clin. Exp. Hematol. 2002, 6, 366–388. [Google Scholar] [CrossRef] [PubMed]
  11. Tadmor, T.; Polliack, A. Hairy cell leukemia: Uncommon clinical features, unusual sites of involvement and some rare associations. Best Pract. Res. Clin. Haematol. 2015, 28, 193–199. [Google Scholar] [CrossRef]
  12. Rahman, K.; Kumari, S.; Singh, M.K.; Gupta, R.; Yadav, G.; Kumari, N.; Nityan, S. Atypical presentation of hairy cell leukemia: Significance of CD200 on flow cytometry. J. Cancer Res. Ther. 2018, 14, 1130–1134. [Google Scholar] [CrossRef]
  13. Troussard, X. Unusual clinical presentations of hairy cell leukemia. Acta Haematol. 2024, 147, 465–466. [Google Scholar] [CrossRef]
  14. Robak, E.; Jesionek-Kupnicka, D.; Robak, T. Skin changes in hairy cell leukemia. Ann. Hematol. 2021, 100, 615–625. [Google Scholar] [CrossRef] [PubMed]
  15. Finan, M.C.; Su, W.P.; Li, C.Y. Cutaneous findings in hairy cell leukemia. J. Am. Acad. Dermatol. 1984, 11 Pt 1, 788–797. [Google Scholar] [CrossRef] [PubMed]
  16. Robak, E.; Jesionek-Kupnicka, D.; Iskierka-Jazdzewska, E.; Janus, A.; Robak, T. Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab. Leuk. Res. 2021, 104, 106571. [Google Scholar] [CrossRef] [PubMed]
  17. Robak, E.; Braun, M.; Robak, T. Leukemia cutis—The current view on pathogenesis, diagnosis, and treatment. Cancers 2023, 15, 5393. [Google Scholar] [CrossRef]
  18. Cho-Vega, J.H.; Medeiros, L.J.; Prieto, V.G.; Vega, F. Leukemia cutis. Am. J. Clin. Pathol. 2008, 129, 130–142. [Google Scholar] [CrossRef]
  19. Parsi, M.; Go, M.S.; Ahmed, A. Leukemia Cutis. [Updated 17 July 2023]. In StatPearls [Internet]; StatPearls Publishing: Tampa, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK541136/ (accessed on 2 August 2024).
  20. Lawrence, D.M.; Sun, N.C.; Mena, R.; Moss, R. Cutaneous lesions in hairy-cell leukemia. Case report and review of the literature. Arch. Dermatol. 1983, 119, 322–325. [Google Scholar] [CrossRef] [PubMed]
  21. Grey, M.R.; Flanagan, N.G.; Kelsey, P.R. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin. Lab. Haematol. 2000, 22, 111–113. [Google Scholar] [CrossRef] [PubMed]
  22. Broccoli, A.; Gandolfi, L.; Pellegrini, C.; Agostinelli, C.; Argnani, L.; Zinzani, P.L. Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature. Tumori 2016, 102 (Suppl. S2), S124–S127. [Google Scholar] [CrossRef]
  23. Gabriel, S.E.; Conn, D.L.; Phyliky, R.L.; Scott, R.E. Vasculitis in hairy cell leukaemia: Review of literature and consideration of possible pathogenic mechanisms. J. Rheumatol. 1986, 13, 1167–1172. [Google Scholar] [PubMed]
  24. Fain, O.; Hamidou, M.; Cacoub, P.; Godeau, B.; Wechsler, B.; Pariès, J.; Stirnemann, J.; Morin, A.S.; Gatfosse, M.; Hanslik, T.; et al. Vasculitides associated with malignancies: Analysis of sixty patients. Arthritis Care Res. 2007, 57, 1473–1480. [Google Scholar] [CrossRef] [PubMed]
  25. Moyers, J.T.; Liu, L.W.; Ossowski, S.; Goddard, L.; Kamal, M.O.; Cao, H. A rash in a hairy situation: Leukocytoclastic vasculitis at presentation of hairy cell Leukemia. Am. J. Hematol. 2019, 94, 1433–1434. [Google Scholar] [CrossRef]
  26. Hasler, P.; Kistler, H.; Gerber, H. Vasculitides in hairy cell leukemia. Semin. Arthritis Rheum. 1995, 25, 134–142. [Google Scholar] [CrossRef]
  27. Ventura, F.; Rocha, J.; Pereira, T.; Marques, H.; Pardal, F.; Brito, C. Sweet syndrome as the presenting symptom of hairy cell leukemia. Dermatol. Online J. 2009, 15, 12. [Google Scholar] [CrossRef] [PubMed]
  28. Levy, R.M.; Junkins-Hopkins, J.M.; Turchi, J.J.; James, W.D. Sweet syndrome as the presenting symptom of relapsed hairy cell leukemia. Arch. Dermatol. 2002, 138, 1551–1554. [Google Scholar] [CrossRef] [PubMed]
  29. Cailly, L.; Gruchet, C.; Maitre, E.; Guidez, S.; Delwail, V.; Systchenko, T.; Moya, N.; Sabirou, F.; Levy, A.; Bobin, A.; et al. Hairy cell leukemia with isolated bone lesions. Clin. Case Rep. 2023, 11, e7343. [Google Scholar] [CrossRef]
  30. Quesada, J.R.; Keating, M.J.; Libshitz, H.I.; Llamas, L. Bone involvement in hairy cell leukemia. Am. J. Med. 1983, 74, 228–231. [Google Scholar] [CrossRef]
  31. Robak, P.; Jesionek-Kupnicka, D.; Kupnicki, P.; Polliack, A.; Robak, T. Bone lesions in hairy cell leukemia: Diagnosis and treatment. Eur. J. Haematol. 2020, 105, 682–691. [Google Scholar] [CrossRef]
  32. Yonal-Hindilerden, I.; Hindilerden, F.; Bulut-Dereli, S.; Yıldız, E.; Dogan, I.O.; Nalcaci, M. Hairy cell leukemia presenting with isolated skeletal involvement successfully treated by radiation therapy and cladribine: A case report and review of the literature. Case Rep. Hematol. 2015, 2015, 803921. [Google Scholar] [CrossRef]
  33. Fasulo, S.M.; Narvaneni, S.; Kumar, V.; Manje Gowda, A.; Sultana, Y. Lytic Bone Lesion: An Unusual presentation of hairy cell leukemia. Cureus 2021, 13, e12959. [Google Scholar] [CrossRef] [PubMed]
  34. Notarfranchi, L.; Russo, F.; Re, F.; Mancini, C.; Martella, E.; Falini, B.; Aversa, F.; Tiacci, E. Hairy cell leukaemia mimicking multiple myeloma. Lancet Oncol. 2019, 20, e187. [Google Scholar] [CrossRef]
  35. VanderMolen, L.A.; Urba, W.J.; Longo, D.L.; Lawrence, J.; Gralnick, H.; Steis, R.G. Diffuse osteosclerosis in hairy cell leukemia. Blood 1989, 74, 2066–2069. [Google Scholar] [CrossRef] [PubMed]
  36. Snell, K.S.; O’Brien, M.M.; Sendelbach, K.; Martino, R. Pathologic fracture occurring 22 years after diagnosis of hairy cell leukemia: Case report and literature review. West. J. Med. 1999, 170, 172–174. [Google Scholar] [PubMed]
  37. Hudson, J.; Cobby, M.; Yates, P.; Watt, I. Extensive infiltration of bone with marrow necrosis in a case of hairy cell leukaemia. Skeletal Radiol. 1995, 24, 228–231. [Google Scholar] [CrossRef] [PubMed]
  38. Lembersky, B.C.; Ratain, M.J.; Golomb, H.M. Skeletal complications in hairy cell leukaemia: Diagnosis and therapy. J. Clin. Oncol. 1988, 6, 1280–1284. [Google Scholar] [CrossRef]
  39. Filippi, A.R.; Franco, P.; Marinone, C.; Tarella, C.; Ricardi, U. Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy. Am. J. Hematol. 2007, 82, 1017–1021. [Google Scholar] [CrossRef]
  40. Lal, A.; Tallman, M.S.; Soble, M.B.; Golubovich, I.; Peterson, L. Hairy cell leukemia presenting as localized skeletal involvement. Leuk. Lymphoma 2002, 43, 2207–2211. [Google Scholar] [CrossRef] [PubMed]
  41. Karmali, R.; Farhat, M.; Leslie, W.; McIntire, M.G.; Gregory, S. Localized bone disease as a presentation of hairy cell leukemia. Clin. Adv. Hematol. Oncol. 2008, 6, 290–294. [Google Scholar] [PubMed]
  42. Robak, P.; Jesionek-Kupnicka, D.; Kupnicki, P.; Polliack, A.; Robak, T. Multifocal osteolytic lesions in hairy cell leukemia-the importance of PET/CT in diagnosis and assessment. Ann. Hematol. 2021, 100, 1641–1645. [Google Scholar] [CrossRef]
  43. Gray, M.T.; Rutherford, M.N.; Bonin, D.M.; Patterson, B.; Lopez, P.G. Hairy-cell leukemia presenting as lytic bone lesions. J. Clin. Oncol. 2013, 31, e410–e412. [Google Scholar] [CrossRef] [PubMed]
  44. Spedini, P.; Tajana, M.; Bergonzi, C. Unusual presentation of hairy cell leukemia. Haematologica 2000, 85, 548. [Google Scholar] [PubMed]
  45. Vardiman, J.W.; Golomb, H.M. Autopsy findings in hairy cell leukemia. Semin. Oncol. 1984, 11, 370–380. [Google Scholar] [PubMed]
  46. Williams, J.P.; Arcement, C.M.; Wong, R.; Robinson, A.E. Diffuse pulmonary disease associated with hairy cell leukemia. Acad. Radiol. 1995, 2, 179–181. [Google Scholar] [CrossRef] [PubMed]
  47. Fields, B.N.; Harris, N.L. A 50-year-old man with hairy cell leukemia, recurrent fever, and variable pulmonary infiltrates. N. Engl. J. Med. 1982, 307, 1693–1700. [Google Scholar] [CrossRef]
  48. Hansen, T.; Constantin, C.; Weber, M.; Titze, U.; Hartmann, F. Bronchoalveolar lavage in hairy cell leukemia with pulmonary infiltration. Pathologe 2019, 40, 529–533. [Google Scholar] [CrossRef]
  49. Uzunhan, Y.; Cadranel, J.; Boissel, N.; Gardin, C.; Arnulf, B.; Bergeron, A. Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas). Rev. Mal. Respir. 2010, 27, 599–610. [Google Scholar] [CrossRef]
  50. Ecsiova, D.; Kamaradova, K.; Nova, M.; Hoffmann, P.; Rozsivalova, P.; Simkovic, M.; Zak, P. Pulmonary damage in a patient with hairy cell leukemia-infectious involvement or hematological disease activity? Case report. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub. 2023, 167, 385–389. [Google Scholar] [CrossRef]
  51. Lemiale, V.; Meignin, V.; Azoulay, É. Hairy cell leukemia with pulmonary infiltrates. In Pulmonary Involvement in Patients with Hematological Malignancies; Azoulay, E., Ed.; Springer: Berlin/Heidelberg, Germany, 2011. [Google Scholar] [CrossRef]
  52. Kimmel, D.W.; Hermann, R.C., Jr.; O’Neill, B.P. Neurologic complications of hairy cell 176 leukemia. Arch. Neurol. 1984, 41, 202–203. [Google Scholar] [CrossRef] [PubMed]
  53. Plenderleith, I.H. Hairy cell leukemia. Can. Med. Assoc. J. 1970, 102, 1056–1060. [Google Scholar] [PubMed]
  54. Wolfe, D.W.; Scopelliti, J.A.; Boselli, B.D. Leukemic meningitis in a patient with hairy cell leukemia. A case report. Cancer 1984, 54, 1085–1087. [Google Scholar] [CrossRef] [PubMed]
  55. Knecht, H.; Budmiger, H.; Groscurth, P.; Streuli, R.A. Central nervous system involvement 182 in hairy cell leukemia. Klin. Wochenschr. 1985, 63, 423–427. [Google Scholar] [CrossRef] [PubMed]
  56. Le Bezu, M.; Pinaudeau, Y.; Poirier, J.; Dreyfus, B. Involvement of the nervous system in hairy cell leukemia. Arch. Neurol. 1985, 42, 839. [Google Scholar] [CrossRef] [PubMed]
  57. Navarrete, D.; Bodega, E. Leukemic meningitis in a patient with hairy cell leukemia. A 186 case report. Nouv. Rev. Fr. Hematol. 1987, 29, 247–249. [Google Scholar] [PubMed]
  58. Chandana, S.R.; Kotecha, R.; Al-Janadi, A.; Chang, H.T.; Conley, B.A. Rare case of hairy cell leukemia with brain parenchymal involvement: A diagnostic dilemma. J. Clin. Oncol. 2013, 31, e186–e188. [Google Scholar] [CrossRef] [PubMed]
  59. McDowell, M.M.; Zhu, X.; Agarwal, N.; Nikiforova, M.N.; Lieberman, F.S.; Drappatz, J. Response of relapsed central nervous system hairy cell leukemia to vemurafenib. Leuk. Lymphoma 2016, 57, 2952–2954. [Google Scholar] [CrossRef] [PubMed]
  60. Perry, A.M.; Matsuda, K.; Wadhwa, V.; Hewitt, D.; Almiski, M.; Johnston, J.B.; Banerji, V. Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine. Blood Adv. 2017, 1, 899–902. [Google Scholar] [CrossRef] [PubMed]
  61. Rosen, D.S.; Smith, S.; Gurbuxani, S.; Yamini, B. Extranodal hairy cell leukemia presenting in the lumbar spine. J. Neurosurg. Spine 2008, 9, 374–376. [Google Scholar] [CrossRef]
  62. Claves, F.; Carras, S.; Burroni, B.; Maitre, E.; Boutonnat, J.; Troussard, X.; Molina, L. Atypical meningeal localization of classical hairy cell leukemia with an impressive response to rituximab and cladribine association. A case report and literature review. eJHaem 2024, 5, 242–246. [Google Scholar] [CrossRef]
  63. Johnson, A.E.; Raju, A.R.; Jacob, A.; Hildebrandt, G.C. Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib. Front. Oncol. 2023, 12, 1100577. [Google Scholar] [CrossRef]
  64. Robak, T.; Puła, A.; Braun, M.; Robak, E. Extramedullary and extranodal manifestations in chronic lymphocytic leukemia-an update. Ann. Hematol. 2024, 103, 3369–3383. [Google Scholar] [CrossRef] [PubMed]
  65. Ito, K.; Harada, K.; Uchino, Y.; Hirano, K.; Sekiguchi, N. A rare clinical case of secondary central nervous system involvement without transformation in hairy cell leukemia: A case report and literature review. Acta Haematol. 2024, 147, 482–488. [Google Scholar] [CrossRef] [PubMed]
  66. Robak, T.; Dietrich, S. Hairy Cell Leukemia. In Indolent Lymphomas. Hematologic Malignancies; Dreyling, M., Ladetto, M., Eds.; Springer: Cham, Switzerland, 2021; pp. 179–194. [Google Scholar] [CrossRef]
  67. Ng, M.H.; Tsang, S.S.; Ng, H.K.; Sriskandavarman, V.; Feng, C.S. An unusual case of hairy cell leukemia: Death due to leukostasis and intracerebral hemorrhage. Hum. Pathol. 1991, 22, 1298–1302. [Google Scholar] [CrossRef] [PubMed]
  68. Dinçol, G.; Kahraman, R. Cryptococcus neoformans meningitis in a patient with hairy cell leukemia. Am. J. Hematol. 2006, 81, 387. [Google Scholar] [CrossRef]
  69. Jiang, K.; Punja, K.G.; Hyrcza, M.D.; Simpson, S.M. Beyond the norm: Unusual orbital manifestation of hairy cell leukemia. Can. J. Ophthalmol. 2024, 59, e285–e287. [Google Scholar] [CrossRef] [PubMed]
  70. Deitch, R.D.; Wilson, F.M. Leukemic reticuloendotheliosis with presenting ocular complaints: Report of acase. Arch. Ophthalmol. 1963, 69, 560–563. [Google Scholar] [CrossRef] [PubMed]
  71. Robinson, A.; Eting, E.; Zeidman, A.; Djaldetti, M.; Mittelman, M.; Savir, H. Ocular manifestation of hairy cell leukemia with dramatic response to 2-chlorodeoxyadenosine. Am. J. Ophthalmol. 1996, 121, 97–99. [Google Scholar] [CrossRef]
  72. Charalel, R.; Jain, A.; Rachakonda, L.; Gaynon, M. Visualdis-turbance as initial presentation of hairy cell leukemia. Eur. J. Ophthalmol. 2009, 19, 318–320. [Google Scholar] [CrossRef] [PubMed]
  73. Di Maria, A.; Redaelli, C.; Canevari, A.; Pagnucco, G.; Martinetti, M.; Bianchi, P.E. Unilateral retinal vasculitis associated with hairy cell leukaemia: Immunogenetic study. Ophthalmologica 1998, 212, 355–357. [Google Scholar] [CrossRef]
  74. Davies, R. Limbal nodules in Sweet’s syndrome. Aust. N. Z. J. Ophthalmol. 1992, 20, 263–265. [Google Scholar] [CrossRef]
  75. Coupland, S.E.; Krause, L.; Delecluse, H.J.; Anagnostopoulos, I.; Foss, H.D.; Hummel, M.; Bornfeld, N.; Lee, W.R.; Stein, H. Lymphoproliferative lesions of the ocular adnexa: Analysis of 112 cases. Ophthalmology 1998, 105, 1430–1441. [Google Scholar] [CrossRef] [PubMed]
  76. Zeidman, A.; Floru, S.; Robinson, A.; Polliack, A.; Djaldeti, M.; Savir, H.; Mittelman, M. Panuveitis responsive to 2-CdA: An unusual ocular presentation of hairy cell leukemia. Leuk. Lymphoma 1996, 20, 501–503. [Google Scholar] [CrossRef] [PubMed]
  77. North, V.S.; Jamerson, E.C.; Plum, W.; Tran, A.Q.; Kazim, M. Spontaneous subperiosteal orbital hematoma as a presenting sign of hairy cell leukemia in a patient with a long-standing orbital implant. Can. J. Ophthalmol. 2023, 58, e189–e191. [Google Scholar] [CrossRef] [PubMed]
  78. Bertram, B.; Schulte, K.; Wolf, S.; Glöckner, W.M.; Reim, M. Retinopathy as the first symptom of hairy cell leukemia. Klin. Monatsbl. Augenheilkd. 1991, 199, 295–297. [Google Scholar] [CrossRef] [PubMed]
  79. Bertram, B.; Schulte, K.; Wolf, S.; Glöckner, W.M. A visual disorder as the initial symptom of hairy cell leukemia. Dtsch. Med. Wochenschr. 1991, 116, 157. [Google Scholar] [PubMed]
  80. Zák, P.; Chrobák, L.; Podzimek, K.; Hejcmanová, D.; Voglová, J.; Dulícek, P.; Mirová, S. An unusual course in hairy-cell leukemia with marked abdominal lymphadenopathy, leukemic infiltration of the cornea and skin changes. Vnitr. Lek. 1996, 42, 463–466. [Google Scholar] [PubMed]
  81. Hejcmanová, D.; Abulgasim, H.A.; Jebavá, R.; Chrobák, L.; Podzimek, K.; Zák, P. Leukemické infiltráty rohovky u nemocné leukémiís “vlasatými bunkami” [Leukemic infiltration of the cornea in a patient with hairy-cell leukemia]. Cesk Slov. Oftalmol. 1995, 51, 152–155. [Google Scholar] [PubMed]
  82. Sattar, M.A.; Cawley, M.I.D. Arthritis associated with hairy cell leukaemia. Ann. Rheum. Dis. 1982, 41, 289–391. [Google Scholar] [CrossRef] [PubMed]
  83. Harden, E.A.; Moore, J.O.; Haynes, R.F. Leukaemia associated arthritis: Indentification of leukaemic cells in synovial fluid using monoclonal and polyclonal antibodies. Arthritis Rheum. 1984, 27, 1306–1308. [Google Scholar] [CrossRef] [PubMed]
  84. Crofts, M.A.; Sharp, J.C.; Joyner, M.Y. Rheumatoid arthritis and hairy-cell leukaemia. Lancet 1979, 314, 203–204. [Google Scholar] [CrossRef] [PubMed]
  85. Westbrook, C.A.; Golde, D.W. Autoimmune disease in hairy-cell leukaemia: Clinical syndromes and treatment. Br. J. Haematol. 1985, 61, 349–356. [Google Scholar] [CrossRef] [PubMed]
  86. Facchini, A.; Mariani, E.; Ferrolli, A.; Mariani, A.R.; Gobbi, M.; Zizzi, F.; Frizziero, L. Hairy cell leukemia and rheumatoid arthritis: Cause or effect. Arthritis Rheum. 1981, 24, 1587. [Google Scholar] [CrossRef]
  87. Anil, V.; Ganipisetti, V.; Harisinghani, K.; Kanugula, A.K. Hairy cell leukemia (HCL) presenting with joint swelling: Case report and literature review of a rare rheumatological manifestation of a hematological disease. Cureus 2023, 15, e35912. [Google Scholar] [CrossRef] [PubMed]
  88. Taylor, H.G.; Davis, M.J.; Hothersall, T.E. Hairy cell leukaemia and rheumatoid arthritis. Br. J. Rheumatol. 1991, 30, 391–392. [Google Scholar] [CrossRef] [PubMed]
  89. Wolfe, F.; Cathey, M.A.; Hawley, D.J. Recombinant gamma interferon in rheumatoid arthritis. Arthritis Rheum. 1986, 30, S18. [Google Scholar]
  90. Raimbourg, J.; Cormier, G.; Stéphane, V.; Tanguy, G.; Bleher, Y.; Maisonneuve, H. Hairy-cell leukemia with inaugural joint manifestations. Jt. Bone Spine 2009, 76, 416–420. [Google Scholar] [CrossRef]
  91. L’Hirondel, J.L.; Troussard, X.; Macro, M.; Courtheoux, F.; Guaydier-Souquières, G.; Mandard, J.C.; Loyau, G. Polyarthrite révélatrice d’une leucémie à tricholeucocytes. Rev. Rhum. Mal. Osteoartic. 1992, 59, 749. [Google Scholar] [PubMed]
  92. Robak, T. Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment. Cancer Treat. Rev. 2011, 37, 3–10. [Google Scholar] [CrossRef] [PubMed]
  93. Troussard, X.; Maitre, E. Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment. J. Cell Mol. Med. 2024, 28, e18060. [Google Scholar] [CrossRef]
  94. Alaggio, R.; Amador, C.; Anagnostopoulos, I.; Attygalle, A.D.; Araujo, I.B.O.; Berti, E.; Bhagat, G.; Borges, A.M.; Boyer, D.; Calaminici, M.; et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 2022, 36, 1720–1748. [Google Scholar] [CrossRef] [PubMed]
  95. Campo, E.; Jaffe, E.S.; Cook, J.R.; Leticia Quintanilla-Martinez, L.; Swerdlow, S.H.; Anderson, K.C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee. Blood 2022, 140, 1229–1253. [Google Scholar] [CrossRef] [PubMed]
  96. Grever, M.; Andritsos, L.; Anghelina, M.; Arons, E.; Banerji, V.; Barrientos, J.; Bhat, S.A.; Blachly, J.; Broccoli, A.; Call, T.; et al. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: Lymphoid neoplasms. Leukemia 2024, 38, 1642–1644. [Google Scholar] [CrossRef] [PubMed]
  97. Janus, A.; Robak, T. Hairy Cell Leukemia. In Leukemia [Internet]; Li, W., Ed.; Exon Publications: Brisbane, Australia, 2022; Volume 3, pp. 33–52. [Google Scholar] [CrossRef] [PubMed]
  98. Venkatesan, S.; Purohit, A.; Aggarwal, M.; Manivannan, P.; Tyagi, S.; Mahapatra, M.; Pati, H.P.; Saxena, R. Unusual presentation of hairy cell leukemia: A case series of four clinically unsuspected cases. Indian J. Hematol. Blood Transfus. 2014, 30 (Suppl. S1), 413–417. [Google Scholar] [CrossRef]
  99. Falini, B.; De Carolis, L.; Tiacci, E. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood 2022, 139, 2294–2305. [Google Scholar] [CrossRef] [PubMed]
  100. Robak, T.; Robak, P. Refractory and relapsed hairy-cell leukemia (HCL): Casting light on promising experimental drugs in clinical trials. Expert Opin. Investig. Drugs 2023, 32, 311–324. [Google Scholar] [CrossRef] [PubMed]
  101. Kreitman, R.J. Hairy cell leukemia: Present and future directions. Leuk. Lymphoma 2019, 60, 2869–2879. [Google Scholar] [CrossRef] [PubMed]
  102. Kaplan, R.P.; Newman, G.; Saperia, D. Pyoderma gangrenosum and hairy cell leukemia. J. Dermatol. Surg. Oncol. 1987, 1, 1029–1031. [Google Scholar] [CrossRef] [PubMed]
  103. Jain, A.; Lad, D.; Prakash, G.; Khadwal, A.; Malhotra, P.; Bal, A.; Mallik, N.; Kumar, N.; Varma, S. Bullous pyoderma gangrenosum associated with hairy cell leukemia and its complete response to cladribine therapy. Indian. J. Hematol. Blood Transfus. 2017, 33, 273–275. [Google Scholar] [CrossRef] [PubMed]
  104. Tombak, A.; Aygun, S.; Serinsoz, E.; Tiftik, E.N. Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine. Korean J. Intern. Med. 2015, 30, 739–741. [Google Scholar] [CrossRef]
  105. Elkon, K.B.; Hughes, G.R.; Catovsky, D.; Clauvel, J.P.; Dumont, J.; Seligmann, M.; Tannenbaum, H.; Esdaile, J. Hairy-cell leukaemia with polyarteritis nodosa. Lancet 1979, 2, 280–282. [Google Scholar] [CrossRef]
  106. Zervas, J.; Vayopoulos, G.; Kaklamanis, P.H.; Zerva, C.H.; Pfessas, P.H. Hairy-cell leukaemia-associated polyarthritis: A report of two cases. Br. J. Rheumatol. 1991, 30, 157–158. [Google Scholar] [CrossRef] [PubMed]
  107. Herold, C.J.; Wittich, G.R.; Schwarzinger, I.; Haller, J.; Chott, A.; Mostbeck, G.; Hajek, P.C. Skeletal involvement in hairy cell leukemia. Skelet. Radiol. 1988, 17, 171–175. [Google Scholar] [CrossRef] [PubMed]
  108. Doma, A.; Škerget, M.; Žagar, I. 18F-FDG PET/CT for staging and evaluation of therapy in a patient with unusual hairy cell leukemia presentation. Clin. Nucl. Med. 2019, 44, e458–e460. [Google Scholar] [CrossRef] [PubMed]
  109. Bennett, C.; Vardiman, J.; Golomb, H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am. J. Med. 1986, 80, 891–896. [Google Scholar] [CrossRef] [PubMed]
  110. Weinstein, R.A.; Golomb, H.M.; Grumet, G.; Gelmann, E.; Schechter, G.P. Hairy cell leukemia: Association with disseminated atypical mycobacterial infection. Cancer 1981, 48, 380–383. [Google Scholar] [CrossRef] [PubMed]
  111. Stanton, D.J.; Quadri, N.Z.; Tanabe, M.B. Concomitantly diagnosed disseminated M kansasii infection and hairy cell leukemia with review of pathophysiology. J. Investig. Med. High. Impact Case Rep. 2024, 12, 23247096241253343. [Google Scholar] [CrossRef]
  112. Schlick, K.; Troch, M.; Placher-Sorko, G.; Faber, V.; Neureiter, D.; Berghoff, A.S.; Preusser, M.; Greil, R.; Hopfinger, G. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: At last, which entity is really carrying the BRAF mutation? Ann. Hematol. 2015, 94, 345–346. [Google Scholar] [CrossRef]
  113. Mitsogianni, M.; Mitsimponas, N.; Crespo, F.; Hartmann, K.A.; Klosterhalfen, B.; Haase, S.; Giagounidis, A. Concomitant non-small cell lung cancer and hairy cell leukemia in a patient harboring BRAF-V600E mutation in both tissues: A case report. Case Rep. Oncol. 2018, 11, 109–113. [Google Scholar] [CrossRef]
  114. AlEnazi, A.; Alhedaithy, R.; Alfayez, A.; Alghonaim, Y. Acute profound sensorineural hearing loss as the initial manifestation of hairy cell leukemia, case report and literature review. Int. J. Surg. Case Rep. 2019, 60, 200–203. [Google Scholar] [CrossRef]
  115. Nageris, B.; Or, R.; Hardan, I.; Polliack, A. Sudden onset deafness as a presenting manifestation of chronic lymphocytic leukemia. Leuk. Lymphoma 1993, 9, 269–271. [Google Scholar] [CrossRef]
  116. Genden, E.M.; Bahadori, R.S. Bilateral sensorineural hearing loss as a first symptom of chronic myelogenous leukemia. Otolaryngol. Head. Neck Surg. 1995, 113, 499–501. [Google Scholar] [CrossRef] [PubMed]
  117. Acar, G.O.; Acioğlu, E.; Enver, O.; Ar, C.; Sahin, S. Unilateral sudden hearing loss as the first sign of chronic myeloid leukemia. Eur. Arch. Otorhinolaryngol. 2007, 264, 1513–2516. [Google Scholar] [CrossRef] [PubMed]
  118. Babakhanlou, R.; Nader, M.E.; Alvarado, Y. A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia. Ann. Hematol. 2023, 102, 3427–3430. [Google Scholar] [CrossRef]
  119. Naraev, B.G.; Linthicum, F.H., Jr. Rapid hearing loss in chronic lymphocytic leukemia. Otol. Neurotol. 2006, 27, 445–446. [Google Scholar] [CrossRef] [PubMed]
  120. Yam, L.T.; Janckila, A.J.; Chan, C.H.; Li, C.Y. Hepatic involvement in hairy cell leukemia. Cancer 1983, 51, 1497–1504. [Google Scholar] [CrossRef]
  121. Dhanesar, G.K.; Livingston, J.; Maroules, M.; Lee, S.H. Hairy cell leukemia: Hepatic affinity status post splenectomy. Cureus 2023, 15, e39830. [Google Scholar] [CrossRef] [PubMed]
  122. Sahar, N.; Schiby, G.; Davidson, T.; Kneller, A.; Apter, S.; Farfel, Z. Hairy cell leukemia presenting as multiple discrete hepatic lesions. World J. Gastroenterol. 2009, 15, 4453–4456. [Google Scholar] [CrossRef] [PubMed]
  123. Al-Saheli, Z.I.; Bazzi, T.; Barthel, B. Oncological management dilemma: A rare presentation of hairy cell leukaemia with hepatic involvement presenting concomitantly with pancreatic adenocarcinoma. BMJ Case Rep. 2022, 15, e252423. [Google Scholar] [CrossRef]
  124. Sen, P.; Shaaban, H.; Modi, T.; Kumar, A.; Guron, G. Hairy Cell Leukemia Presenting with Duodenal Involvement Duodenum: A Case Report. N. Am. J. Med. Sci. 2015, 7, 288–290. [Google Scholar] [CrossRef] [PubMed]
  125. Tariq, S.; Bin Hamid, M.A.; Rahman, N.; Oleary, L.; Wong, K.; Sehbai, A. Unusual presentation of gastric cancer during treatment of hairy cell leukemia: Exploring the etiological basis of this rare phenomenon. Cancer Pathog. Ther. 2023, 1, 146–148. [Google Scholar] [CrossRef] [PubMed]
  126. Iwashige, A.; Hirosawa, M.; Tsukada, J. Hairy cell leukemia presenting with progressive pericarditis and pleuritis. Ann. Hematol. 2018, 97, 2527–2528. [Google Scholar] [CrossRef]
  127. Koczwara, B.; Spangenthal, E.; Bernstein, S.H. The development of congestive cardiac failure in a patient with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk. Lymphoma 1997, 26, 413–415. [Google Scholar] [CrossRef] [PubMed]
  128. Rosenthal, R.A.; Lowenstein, J.M. Inhibition of phosphorylation of troponin in rat heart by adenosine and 5-chloro-5-deoxyadenosine. Biochem. Pharmacol. 1991, 42, 685–692. [Google Scholar] [CrossRef] [PubMed]
  129. Ramasamy, C.; Dubashi, B.; Rekha, J.S.; Basu, D.; Jain, A.; Dutta, T.K. Hairy cell leukemia masquerading as infective endocarditis. Indian. J. Hematol. Blood Transfus. 2013, 29, 84–86. [Google Scholar] [CrossRef] [PubMed]
  130. Sucak, G.T.; Haznedar, R.; Yalçin, R. Reversible cardiomyopathy in a patient with hairy cell leukaemia. Postgrad. Med. J. 1998, 74, 313–314. [Google Scholar] [CrossRef] [PubMed]
  131. Anderson, L.A.; Engels, E.A. Autoimmune conditions and hairy cell leukemia: An exploratory case-control study. J. Hematol. Oncol. 2010, 3, 35. [Google Scholar] [CrossRef]
  132. Pilichowska, M.; Shariftabrizi, A.; Mukand-Cerro, I.; Miller, K. Primary hairy cell leukemia/lymphoma of the breast: A case report and review of the literature. Case Rep. Pathol. 2014, 2014, 497027. [Google Scholar] [CrossRef] [PubMed]
  133. Aggarwal, N.; Neupane, R.; Thorburn, C.; Chisti, M.; Jamil, L.H. Hairy cell leukemia: A rare differential for a pancreatic mass. Am. J. Gastroenterol. 2023, 118, 1562–1563. [Google Scholar] [CrossRef]
Cancers 16 03054 g001
Figure 1. Representative images of hairy cell leukemia bone lesions. Pathologic FDG uptake in the ribs, left humerus, vertebral body Th10, sacrum, right iliac, pubic bone and ischium imaged in PET/CT imaging (A). Mixed osteolytic and osteoblastic lesions in the sacrum in PET/CT imaging (B) and vertebrum in PET/CT imaging (C). Bone marrow infiltrate of HCL in Haematoxyllin and Eosin staining, magnification of 100× (D) and in staining for CD20, magnification of 100× (E).
Figure 1. Representative images of hairy cell leukemia bone lesions. Pathologic FDG uptake in the ribs, left humerus, vertebral body Th10, sacrum, right iliac, pubic bone and ischium imaged in PET/CT imaging (A). Mixed osteolytic and osteoblastic lesions in the sacrum in PET/CT imaging (B) and vertebrum in PET/CT imaging (C). Bone marrow infiltrate of HCL in Haematoxyllin and Eosin staining, magnification of 100× (D) and in staining for CD20, magnification of 100× (E).
Cancers 16 03054 g001
Cancers 16 03054 g002
Figure 2. Pulmonary involvement of HCL. X-ray chest PA view shows unilateral right diffuse pulmonary infiltrates (A). High-resolution computed tomography reveals septal thickening and multiple small and diffusely-merging focal consolidations with ground glass opacities in frontal (B), side (C) and transversal projection (D). Lung biopsy showing an infiltrate of HCL in Haematoxyllin and Eosin staining, magnification of 100× (E) and in staining for CD20, magnification of 100× (F). Damage or introduction of infection.
Figure 2. Pulmonary involvement of HCL. X-ray chest PA view shows unilateral right diffuse pulmonary infiltrates (A). High-resolution computed tomography reveals septal thickening and multiple small and diffusely-merging focal consolidations with ground glass opacities in frontal (B), side (C) and transversal projection (D). Lung biopsy showing an infiltrate of HCL in Haematoxyllin and Eosin staining, magnification of 100× (E) and in staining for CD20, magnification of 100× (F). Damage or introduction of infection.
Cancers 16 03054 g002
Table 1. Rare symptoms in hairy cell leukemia.
Table 1. Rare symptoms in hairy cell leukemia.
SymptomsEtiology Clinical CharacteristicsDiagnostic ProceduresReferences
Skin changesLeukemic infiltration, autoimmune reactions, infections, secondary neoplasms and drug-induced symptomsDisseminated erythematous maculopapules and nodules, vasculitis, neutrophilic dermatoses and periarteritis nodosaSkin biopsy[14,15,16,17,18,19,20,21,22,23,24,25,26,27,28]
Bone lesionsLeukemic skeletal infiltrations Localized pain, multifocal osteolytic and osteoblastic lesions and severe osteoporosis X-rays, MRI, CT, PET and core biopsy[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]
Pulmonary changes Leukemic infiltration, mediastinal infiltrations and infections Pulmonary symptoms: cough, dyspnea, chest pain and hemoptysisChest X-rays, CT and lung biopsy if antibiotics and antifungal treatment are not effective[45,46,47,48,49,50,51]
Neurologic manifestationsLeukemic infiltration and infections Confusion, aphasia, headache, meningeal syndrome, motor ataxia, dizziness, weakness, slurred speech, fatigue and blurry visionImaging studies (NMR, CT, PET) and lumbar puncture[52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68]
Ocular symptomsLeukemic infiltration, bleeding and infectionsOcular or orbital manifestations, panuveitis, conjunctivitis, leukemic corneal infiltration, retinopathy and visual disturbanceOphthalmological examination, CT and biopsy of ocular mass[69,70,71,72,73,74,75,76,77,78,79,80,81]
Rheumatological symptoms Immune-mediated or direct, non-immune mechanism Athritis, joint pain and swelling, erythema and tenderness Serologic tests, X-rays and cytologic evaluation of synovial fluid[82,83,84,85,86,87,88,89,90,91]
Abbreviations: BM—bone marrow, CNS—central nervous system, CR—complete response, CT—computed tomography, HCL—hairy cell leukemia, MRI—magnetic resonance imaging and PET—positron emission tomography.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Robak, T.; Braun, M.; Janus, A.; Guminska, A.; Robak, E. Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview. Cancers 2024, 16, 3054. https://doi.org/10.3390/cancers16173054

AMA Style

Robak T, Braun M, Janus A, Guminska A, Robak E. Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview. Cancers. 2024; 16(17):3054. https://doi.org/10.3390/cancers16173054

Chicago/Turabian Style

Robak, Tadeusz, Marcin Braun, Agnieszka Janus, Anna Guminska, and Ewa Robak. 2024. "Rare Clinical Symptoms in Hairy Cell Leukemia: An Overview" Cancers 16, no. 17: 3054. https://doi.org/10.3390/cancers16173054

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop